|
|
|
| Clinical efficacy of Danshen granules combined with metoprolol in treatment of elderly patients with preserved ejection fraction heart failure complicated with coronary heart disease |
| LIN Zhen, JI Lifen, OUYANG Shandan, GUO Luwei, LI Yang, DU Jiangtao |
| Pharmacy Department, the 73rd Group Military Hospital of PLA Army, Xiamen 361000, China |
|
|
|
|
Abstract Objective To explore the therapeutic effect of Danshen Granules combined with metoprolol in the treatment of elderly patients with preserved ejection fraction heart failure complicated with coronary heart disease, and to analyze its influence on inflammatory factors and the levels of NT proBNP and MMP-9. Methods A retrospective analysis was conducted on the clinical data of 274 elderly patients with preserved ejection fraction heart failure and coronary heart disease admitted to the 73rd Group Military Hospital of PLA Arny from December 2019 to December 2022. The patients were divided into control group (n=111) and observation group (n=163) according to drug use. The control group was treated with metoprolol, while the observation group was treated with a combination of metoprolol and Danshen granules. The clinical efficacy , cardiac function [left ventricular end systolic diameter (LVESD),left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD)], vascular endothelial function [endothelin 1 (ET-1), nitric oxide (NO)], inflammatory factors [hypersensitive C-reactive protein (hs CRP), soluble intercellular adhesion molecule-1 (sICAM-1) and interleukin-6 (IL-6) ], serum levels of NT - proBNP and MMP-9 , and occurrence of adverse reactions were compared between two groups. Results After treatment, the clinical effective rate of the observation group was higher than that of the control group (93.87% vs. 81.98%) (P<0.05). After treatment, the cardiac function of the two groups was improved. The LVEDD, LVEF and LVESD in the observation group were better than those in the control group [(47.36±6.43)mm vs. (50.86±4.27) mm; (59.93±4.73)% vs. (56.38±4.21)%; (29.46±4.13) mm vs. (33.56±4.68 ) mm; P<0.05]. After treatment, the vascular endothelial function of the two groups was improved. The levels of ET-1 and NO in the observation group were better than those in the control group [(51.46±7.75) ng/L vs. (59.69±6.73) ng/L; (101.89±11.73) μmol/L vs. (90.71±10.83) μmol/L; P<0.05]. After treatment, the levels of inflammatory factors in the two groups were improved. The levels of hs-CRP, sI-CAM-1 and IL-6 in the observation group were better than those in the control group [(7.27±0.83) mg/L vs. (9.37±0.95) mg/L; (194.68±20.01) ng/ml vs. (223.64±28.79) ng/ml; (27.62±2.93) pg/ml vs. (32.60±3.76) pg/ml; P<0.05]. After treatment, the levels of NT-proBNP and MMP-9 in the two groups were improved. The levels of NT-proBNP and MMP-9 in the observation group were better than those in the control group [(324.19±173.06) ng/L vs. (395.69±186.79) ng/L; (146.72±15.85)μg/L vs. (163.76±16.14)μg/L; P<0.05]. There was no statistical difference in the occurrence of adverse reactions between two groups (P<0.05). Conclusions The combination of Danshen granules and metoprolol has a significant therapeutic effect on elderly patients with preserved ejection fraction heart failure complicated with coronary heart disease, which can improve inflammation and reduce serum levels of NT proBNP and MMP-9.
|
|
Received: 11 September 2023
|
|
|
|
|
|
| [1] |
张建军.接轨国际指南、彰显中国特色——《中国心力衰竭诊断和治疗指南2018》解读[J].中国临床医生杂志, 2019,47(4):398-402,374.
|
| [1] |
张建军.接轨国际指南、彰显中国特色——《中国心力衰竭诊断和治疗指南2018》解读[J].中国临床医生杂志, 2019,47(4):398-402,374.
|
| [2] |
闫少华, 耿 巍, 田 祥.射血分数保留心力衰竭发病机制及治疗研究进展[J].临床合理用药, 2023,16(13): 166-169.
|
| [2] |
闫少华, 耿 巍, 田 祥.射血分数保留心力衰竭发病机制及治疗研究进展[J].临床合理用药, 2023,16(13): 166-169.
|
| [3] |
陈 莹, 郑 辉, 何 玉.合并冠心病的老年射血分数保留心力衰竭患者营养状态与预后的关系研究[J].中国全科医学,2023,26(3):335-342.
|
| [3] |
陈 莹, 郑 辉, 何 玉.合并冠心病的老年射血分数保留心力衰竭患者营养状态与预后的关系研究[J].中国全科医学,2023,26(3):335-342.
|
| [3] |
董晨艳, 陈海燕, 李 源.复方丹参滴丸联合替格瑞洛治疗冠心病PCI术后心绞痛的临床疗效[J].中西医结合心脑血管病杂志,2022,20(2):292-294.
|
| [3] |
董晨艳, 陈海燕, 李 源.复方丹参滴丸联合替格瑞洛治疗冠心病PCI术后心绞痛的临床疗效[J].中西医结合心脑血管病杂志,2022,20(2):292-294.
|
| [4] |
陈 璐, 聂永伟, 张燕欣,等.丹参单体化合物及丹参类制剂对心脑血管系统信号通路影响的研究进展[J].药物评价研究,2021,44(11):2333-2342.
|
| [4] |
陈 璐, 聂永伟, 张燕欣,等.丹参单体化合物及丹参类制剂对心脑血管系统信号通路影响的研究进展[J].药物评价研究,2021,44(11):2333-2342.
|
| [5] |
周京敏, 王 华, 黎励文.射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J].中国循环杂志, 2023, 38 (4):375-393.
|
| [5] |
周京敏, 王 华, 黎励文.射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J].中国循环杂志, 2023, 38 (4):375-393.
|
| [6] |
Editorial:Major changes made by Criteria Committee of the New York Heart Association[J].Circulation,1974,49(3):390.
|
| [6] |
Editorial:Major changes made by Criteria Committee of the New York Heart Association[J].Circulation,1974,49(3):390.
|
| [7] |
Knuuti J, Wijns W, Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020, 41(3):407-477.
|
| [7] |
Knuuti J, Wijns W, Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020, 41(3):407-477.
|
| [8] |
国家卫生计生委合理用药专家委员会中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志(电子版),2016,8(9):19-66.
|
| [8] |
国家卫生计生委合理用药专家委员会中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志(电子版),2016,8(9):19-66.
|
| [9] |
张洪霞, 张钦宝, 白景玉.沙库巴曲缬沙坦钠对射血分数保留心力衰竭患者的治疗效果及不良心血管事件发生的影响[J].世界复合医学,2022,8(12):181-184.
|
| [9] |
张洪霞, 张钦宝, 白景玉.沙库巴曲缬沙坦钠对射血分数保留心力衰竭患者的治疗效果及不良心血管事件发生的影响[J].世界复合医学,2022,8(12):181-184.
|
| [10] |
陈 蓉, 于子翔,李 芊, 等.2型糖尿病对冠心病合并射血分数保留心力衰竭患者的预后研究[J].中国循证医学杂志,2022,22(5):517-523.
|
| [10] |
陈 蓉, 于子翔,李 芊, 等.2型糖尿病对冠心病合并射血分数保留心力衰竭患者的预后研究[J].中国循证医学杂志,2022,22(5):517-523.
|
| [11] |
张燕玲,黄 莉,陈建新.美托洛尔联合依折麦布治疗老年冠心病的应用效果[J].中国医药指南, 2023, 21 (13): 29-32.
|
| [11] |
张燕玲,黄 莉,陈建新.美托洛尔联合依折麦布治疗老年冠心病的应用效果[J].中国医药指南, 2023, 21 (13): 29-32.
|
| [12] |
郭肖雅.沙库巴曲缬沙坦联合美托洛尔治疗冠心病并慢性心力衰竭的临床效果研究[J].罕少疾病杂志,2023,30(05):42-43,51.
|
| [12] |
郭肖雅.沙库巴曲缬沙坦联合美托洛尔治疗冠心病并慢性心力衰竭的临床效果研究[J].罕少疾病杂志,2023,30(05):42-43,51.
|
| [13] |
唐雪梅,徐岩鹰,万成涛.丹参酮ⅡA磺酸钠注射液联合美托洛尔对老年高血压合并心力衰竭患者的疗效[J].心血管康复医学杂志,2021,30(6):699-703.
|
| [13] |
唐雪梅,徐岩鹰,万成涛.丹参酮ⅡA磺酸钠注射液联合美托洛尔对老年高血压合并心力衰竭患者的疗效[J].心血管康复医学杂志,2021,30(6):699-703.
|
| [14] |
康艳生,刘静静,张 伟,等.复方丹参颗粒、复方丹参胶囊、复方丹参片与复方丹参滴丸对冠心病心绞痛患者疗效、炎性因子及氧化应激指标的影响[J].药物评价研究,2020,43(2):287-292.
|
| [14] |
康艳生,刘静静,张 伟,等.复方丹参颗粒、复方丹参胶囊、复方丹参片与复方丹参滴丸对冠心病心绞痛患者疗效、炎性因子及氧化应激指标的影响[J].药物评价研究,2020,43(2):287-292.
|
| [15] |
古 忆,周建松,夏思良,等.阿托伐他汀对慢性心力衰竭RAAS系统与炎性因子的影响[J].临床心血管病杂志,2016,32(1):94-96.
|
| [15] |
古 忆,周建松,夏思良,等.阿托伐他汀对慢性心力衰竭RAAS系统与炎性因子的影响[J].临床心血管病杂志,2016,32(1):94-96.
|
| [16] |
阮宏云,王临光,冯春光,等.参附注射液对慢性心力衰竭急性发作患者的血流动力学及炎性因子的影响[J].中华中医药杂志,2014,29(11):3608-3610.
|
| [16] |
阮宏云,王临光,冯春光,等.参附注射液对慢性心力衰竭急性发作患者的血流动力学及炎性因子的影响[J].中华中医药杂志,2014,29(11):3608-3610.
|
| [17] |
李晓利,王耀辉,范 利,等.老年患者心力衰竭生物标志物N末端B型钠尿肽前体水平检测及影响因素分析[J].中华老年心脑血管病杂志,2020,22(10):1012-1015.
|
| [17] |
李晓利,王耀辉,范 利,等.老年患者心力衰竭生物标志物N末端B型钠尿肽前体水平检测及影响因素分析[J].中华老年心脑血管病杂志,2020,22(10):1012-1015.
|
| [18] |
李延辉,陈 瑶,黄 莺,等.老年射血分数保留及舒张性心力衰竭患者基质金属蛋白酶9、可溶性人基质裂解素2检测对心功能评估的价值[J].中国老年学杂志,2019,39(6):1287-1290.
|
| [18] |
李延辉,陈 瑶,黄 莺,等.老年射血分数保留及舒张性心力衰竭患者基质金属蛋白酶9、可溶性人基质裂解素2检测对心功能评估的价值[J].中国老年学杂志,2019,39(6):1287-1290.
|
| [19] |
黄 铭,韩 冬,昌 震.柴胡疏肝散合血府逐瘀汤加减对冠心病稳定型心绞痛的疗效及对负面情绪的影响[J].中药材,2022,45(12):3007-3011.
|
| [19] |
黄 铭,韩 冬,昌 震.柴胡疏肝散合血府逐瘀汤加减对冠心病稳定型心绞痛的疗效及对负面情绪的影响[J].中药材,2022,45(12):3007-3011.
|
|
|
|
2024, Vol. 35 
